title: The Protective Effect of Poloxamer-188 on Platelet Functions.
abstract: BACKGROUND
  Poloxamer-188 (MST-188) is effective in the repair/recovery of damaged cell membranes. MST-188 is a promising agent for protecting blood cell viability. The aim of the study is to test the hypothesis that MST-188 can extend the duration of platelet function.
  
  
  METHODS
  Blood samples were collected from 20 healthy volunteers. MST-188 (10 or 2 mg/mL) containing platelet-rich plasma (PRP) was prepared with 2 procedures. First, PRP prepared from MST-188 added whole blood (WB); second, MST-188 was added to PRP. These were referred to MST-188-WB preparation (WBP) and MST-188-PRP preparation (PRPP), respectively. For control, saline was used in the same manner. Agonist-induced aggregation (AIA) studies were performed at 30, 180, and 300 minutes using Platelet Aggregation Profiler (PAP-8) aggregometer (Bio/Data Corporation, Horsham, Pennsylvania) and Adenosine diphosphate (ADP), arachidonic acid, collagen, and epinephrine as agonists at final concentration of 20 µM, 500 µg/mL, 0.19 mg/mL, and 100 µM, respectively.
  
  
  RESULTS
  There was a protective effect of MST-188 on ADP and collagen AIA. At 300 minutes, ADP AIA was found to be 50.2% higher than saline control in 2-mg WBP, 43% at 10-mg PRPP, and 10.4% at 2-mg PRPP. Protective effect of on collagen AIA was 65.9% in 2-mg WBP, 42.74% at 10-mg PRPP, and 11.42% at 2-mg PRPP. In comparison between 30 and 300 minutes, MST-188 showed significant protection in terms of ADP and collagen receptors and for both types of preparations (WBP and PRPP).
  
  
  CONCLUSIONS
  The protective effects of MST-188 on ADP- and collagen-induced platelet aggregation may contribute to the preservation of platelet functionality upon storage in blood banks.
authors.affiliation: 1 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Nil
authors.initials: N
authors.lastname: Guler
authors.affiliation: 1 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Schuharazad
authors.initials: S
authors.lastname: Abro
authors.affiliation: 2 Mast Therapeutics, Inc, San Diego, CA, USA.
authors.forename: Marty
authors.initials: M
authors.lastname: Emanuele
authors.affiliation: 1 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Omer
authors.initials: O
authors.lastname: Iqbal
authors.affiliation: 1 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Hoppensteadt
authors.affiliation: 1 Department of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL, USA.
authors.forename: Jawed
authors.initials: J
authors.lastname: Fareed
mesh_terms: D001792:Blood Platelets / Q000166:cytology / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D020442:Poloxamer / Q000494:pharmacology*
chemical_list: D020442:Poloxamer
keywords: Poloxamer-188 (MST-188); aggregation; blood bank; platelet